drugset

drugset / Trial / NCT00864721

Sunitinib Non Small Cell Lung Cancer Patients Over 70

NCT00864721 ↗

Phase 2 Completed 63 enrolled US Oncology Research Pfizer · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to find out what effects (good and bad) sunitinib has on patients and their NSCLC.

Timeline

Start: 2009-02
Primary completion: 2012-07
Completion: 2012-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sunitinib	Small molecule	37.5 mg	Oral

Indications